Skip to main content
NewslettersWatchlist

Verona Pharma Plc ADR(VRNA-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low12.97
Day High13.50
Open:13.42
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Motley Fool
3 Healthcare Stocks That Have Outperformed Nvidia Since 2022
Motley Fool
3 Stocks That Could Be Monster Winners in 2024
Motley Fool
Lucid Is Revving Up, but This Nasdaq Stock Is Jumping Even More
MarketBeat
Small-Cap Catalyst Pharma Is Among Market's Best Price Performers
Globe Newswire
Verona Pharma plc Announces Pricing of Upsized Underwritten Public Offering
Globe Newswire
Verona Pharma plc Announces Proposed Underwritten Public Offering
Motley Fool
Why Verona Pharma Stock Is Skyrocketing Today
Spotlight Growth
Verona Pharma (NASDAQ: VRNA) Reports its Phase 3 ENHANCE-2 Trial of Ensifentrine Met Primary Endpoint in Treating COPD
Globe Newswire
Verona Pharma Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Globe Newswire
Verona Pharma Announces Ensifentrine Meets Primary Endpoint in Phase 3 ENHANCE-2 Trial for COPD
Globe Newswire
Verona Pharma to Announce Top-line Data from Phase 3 ENHANCE-2 Trial of Nebulized Ensifentrine for COPD
PR Newswire
The Healthcare Companies Fighting the World's Biggest Killers
Globe Newswire
Verona Pharma Completes Enrollment in Phase 3 ENHANCE-1 Trial Evaluating Ensifentrine for Maintenance Treatment of COPD
Globe Newswire
Verona Pharma to Host KOL Event on June 16, 2022
Globe Newswire
Verona Pharma to Present at Jefferies Healthcare Conference
Globe Newswire
Verona Pharma to Present Successful TQT Analysis Demonstrating No Clinically Relevant Effect on Cardiac Conduction at the American Thoracic Society 2022
Globe Newswire
Verona Pharma Announces May 2022 Investor Conference Participation
Globe Newswire
Verona Pharma Reports First Quarter 2022 Financial Results and Provides Corporate Update
Globe Newswire
Verona Pharma to Report First Quarter 2022 Financial Results and Provide Corporate Update
Globe Newswire
James Brady Joins Verona Pharma as Non-Executive Director
Globe Newswire
Verona Pharma Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
Globe Newswire
Verona Pharma to Report Fourth Quarter and Full Year 2021 Financial Results and Provide Corporate Update
Globe Newswire
Verona Pharma Completes Enrollment in Phase 3 ENHANCE-2 Trial Evaluating Ensifentrine for Maintenance Treatment of COPD
Globe Newswire
Verona Pharma Completes Enrollment in ENHANCE-1 48-week Subset
Globe Newswire
Verona Pharma to Present at H.C. Wainwright BioConnect Virtual Conference
Globe Newswire
Verona Pharma Reports TQT Study Successfully Demonstrated No Clinically Relevant Effect on Cardiac Conduction
Globe Newswire
Verona Pharma Reports Third Quarter 2021 Financial Results and Provides Corporate Update
Globe Newswire
Verona Pharma Announces November 2021 Investor Conference Participation
Globe Newswire
Verona Pharma to Report Third Quarter 2021 Financial Results and Provide Corporate Update
Globe NewsWire
Verona Pharma Presents Pharmacokinetic Data with Ensifentrine at the European Respiratory Society International Congress 2021
Globe NewsWire
Verona Pharma to Present at H.C. Wainwright 23rd Annual Global Investment Conference
Globe NewsWire
Verona Pharma Reports Second Quarter 2021 Financial Results and Provides Corporate Update

Profile

Verona Pharma plc is a clinical-stage biopharmaceutical company. It researches, discovers and develops therapeutic drugs to treat respiratory diseases primarily in the United Kingdom and North America. Verona Pharma plc is based in London, the United Kingdom.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.